Clinical Trial Update: Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan [Phase 1, Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 1/2 trial of BMS-354825 (dasatinib) in Japanese patients with chronic myelogenous leukemia who are resistant to or i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• BMS-354825 (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED